BRISTOL MYERS SQUIBB CO
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2025 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2025 | MZL | marginal zone lymphoma |
|---|---|---|---|
| ANDA | Abbreviated New Drug Application | Mirati | Mirati Therapeutics, Inc. |
| AstraZeneca | AstraZeneca PLC | NDA | New Drug Application |
| API | Active Pharmaceutical Ingredient | NTD | non-transfusion-dependent |
| AOCL | Accumulated other comprehensive loss | NHL | Non-Hodgkin's Lymphoma |
| BioArctic | BioArctic AB | oHCM | Obstructive Hypertrophic Cardiomyopathy |
| Celgene | Celgene Corporation | Ono | Ono Pharmaceutical Co., Ltd |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | PD-1 | programmed cell death protein 1 |
| cHL | classical Hodgkins Lymphoma | PD-L1 | programmed death-ligand 1 |
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act |
| Dr. Reddy's Laboratories | Dr. Reddy’s Laboratories, Limited and Dr. Reddy’s Laboratories, Inc. | Pfizer | Pfizer, Inc. |
| EC | European Commission | PFS | progression-free survival |
| EPS | earnings per share | PsA | psoriatic arthritis |
| EU | European Union | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 |
| Evotec | Evotec SE | R&D | research and development |
| Exchange Act | the Securities Exchange Act of 1934 | RDFV | readily determinable fair values |
| FASB | Financial Accounting Standards Board | REMS | risk evaluation and mitigation strategy |
| FDA | U.S. Food and Drug Administration | Roche | F. Hoffman-La Roche & Co. |
| GAAP | generally accepted accounting principles | RRMM | relapsed or refractory multiple myeloma |
| GTN | gross-to-net | Sanofi | Sanofi S.A. |
| HCM | hypertrophic cardiomyopathy | SEC | U.S. Securities and Exchange Commission |
| HHS | Health and Human Services | SPC | Supplementary Protection Certificate |
| IPRD | in-process research and development | SystImmune | SystImmune, Inc. |
| IRA | Inflation Reduction Act of 2022 | TD | transfusion-dependent |
| IRS | Internal Revenue Service | TNBC | triple negative breast cancer |
| IT | Information Technology | U.K. | United Kingdom |
| Merck | Merck & Co., Inc., Rahway, NJ, USA | U.S. | United States |
| MCL | mantle cell lymphoma | VAT | value added tax |
| MRD | minimal residual disease | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.